AX-2025-020505 · Pemvidutide · KP lot KP-2501-G6332

Section 1

Results

Measured against the index acceptance specification for the incretin analogues and co-agonists class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 25 min gradient, 214 nm	98.34	% area	≥ 96.0	PASS
Total impurities	RP-HPLC, sum of reported peaks	1.66	% area	≤ 4.0	PASS
Largest single impurity	RP-HPLC — aspartimide (−18 Da)	0.74	% area	≤ 1.00	PASS
Identity — theoretical monoisotopic mass	calculated from molecular formula	4679.4014	Da	—	NOT TESTED
Identity — observed monoisotopic mass	LC-MS, unit resolution (single quadrupole)	4679.4445	Da	—	NOT TESTED
Mass accuracy	observed vs theoretical	+9.2	ppm	± 15	PASS
Total peptide content	by difference from the gravimetric mass balance	86.59	%w/w	—	NOT TESTED
Target-compound content	total peptide content × purity	85.15	%w/w	—	NOT TESTED
Gross fill (as weighed)	five-place balance, under nitrogen	2.05	mg	1.8 mg declared	NOT TESTED
Recovered target peptide	gross fill × target content	1.746	mg	1.8 mg claim	NOT TESTED
Recovery against label claim	recovered ÷ claim	97.0	%	90.0 – 110.0	PASS
Water content	Karl Fischer, coulometric, duplicate	5.44	%	≤ 8.0	PASS
Counter-ion (TFA)	anion-exchange ion chromatography	7.52	%	≤ 12.0	PASS
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.45	%	—	NOT TESTED
Endotoxin	kinetic chromogenic LAL	1.06	EU/mg	≤ 5.0	PASS
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	White lyophilised cake, intact	—	white to off-white intact cake	PASS
Reconstitution clarity	reconstituted per submitter procedure	Clear after 90 s gentle swirling, no particulates	—	clear, no visible particulates	PASS
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	3.53	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 25 min gradient	16.14	min	17.24 ± 0.50 (normalised)	FAIL
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	1.28	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	49,536	—	≥ 20,000	PASS
Resolution to nearest impurity	vs [D-Aib2]-diastereomer	0.56	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 25 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 49,536, and skew follows the reported asymmetry factor of 1.28. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.74 % impurity against a 98.34 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	Pemvidutide — main peak	16.14	4,779,629	98.34	—
2	aspartimide (−18 Da)	16.62	35,966	0.74	-18.011
3	des-EDA linker (−60 Da)	15.41	26,246	0.54	-60.048
4	truncated (3-39)	14.85	11,665	0.24	-222.112
5	[D-Aib2]-diastereomer	15.97	6,804	0.14	0.000
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 3

Mass spectrum and identity

Theoretical monoisotopic mass 4679.4014 Da, computed from C218H336N48O66. All ppm figures on this site are against monoisotopic values — see why that matters.

Figure 2. ESI charge-state envelope, unit-resolution instrument. Sticks are placed at m/z = (M + z × 1.007276)/z for the observed neutral mass of 4679.4445 Da. Sodium (+21.982/z) and potassium (+37.956/z) adducts are shown where the parent charge state exceeds 25 % relative abundance; they are adducts of the same molecule and are not impurities.

Charge	Theoretical m/z	Observed m/z	Δ m/z	Rel. abundance (%)
6+	780.9075	780.9147	0.0072	8.9
5+	936.8876	936.8962	0.0086	53.7
4+	1170.8576	1170.8684	0.0108	100.0
3+	1560.8077	1560.8221	0.0144	56.9

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Component	Determination	%w/w of cake
Water	Karl Fischer	5.44
Counter-ion (TFA)	ion chromatography	7.52
Residual solvent + inorganic residue	estimated	0.45
Total peptide content	by difference	86.59
Total		100.00 CLOSES

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	98.20	98.34	divergence -0.14 pp vs batch median
Total impurities (% area)	not stated	1.66
Largest single impurity (% area)	not stated	0.74
Water (%)	4.1	5.44
Counter-ion (%)	not stated	7.52
Peptide content (%w/w)	not stated	86.59
Endotoxin (EU/mg)	not stated	1.06
Method stated on certificate	YES	—	column, gradient and wavelength given

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Buyer-sourced
Evidentiary weight: Strongest available evidence in this index.
Chain of custody: Retail purchase → submitter (ambient, 4 d) → laboratory (hand-carried, 12 d) → assay.
Assay date: 23 Feb 2025
Submitted to the index: 03 Mar 2025
Laboratory: Medutest, Ljubljana, Slovenia
Method basis: 25 min gradient · unit-resolution MS
Verification status: IDENTITY CONSISTENT

What this report does not establish

That the compound is not a near-isobaric alternative. Identity was confirmed at unit mass resolution, which cannot exclude species differing by 1 or 2 Da. The specific alternatives not excluded are named in the identity block above.
That the material is sterile. Sterility was not tested.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations 3

Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.

chain_custody03 Mar 2025

Custody from checkout to injection is documented on this record. Provenance plus custody is what makes a single result generalise past the vial it came from.

moq_reality03 Mar 2025

Retail purchases test the retail channel. Manufacturer-tier material bought at kilogram scale is a different product with different documentation, and this index sees very little of it.

plate_count03 Mar 2025

Efficiency is the lever that does not change selectivity, so it improves resolution without moving anything else. Longer column, smaller particle, or lower flow, in that order of cost.

Section 7

Related records

Same batch — lot KP-2501-G6332 n=1

This is the only report on this lot. One report is not a batch characterisation.

Batch rollup and reproducibility assessment →

Cross-sections

Other recent Pemvidutide records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Result
AX-2025-020820	CPC	CPC-2507-H1165	Kestrel	2025-Q4	98.17	4.36	—	Buyer-sourced	PASS
AX-2025-020818	CPC	CPC-2507-H1165	Medutest	2025-Q4	98.10	3.84	—	Buyer-sourced	PASS
AX-2025-020819	CPC	CPC-2507-H1165	PeptideMeter	2025-Q4	97.90	3.89	101.6	Supplier-supplied	PASS
AX-2025-021092	BCH	BCH-2506-G4536	Janoshik	2025-Q3	97.97	5.58	—	Supplier-supplied	PASS
AX-2025-018548	QYB	QYB-2502-V4343	Janoshik	2025-Q3	98.81	3.70	107.3	Buyer-sourced	PASS
AX-2025-018547	QYB	QYB-2502-V4343	PeptideMeter	2025-Q3	98.66	4.36	91.0	Buyer-sourced	PASS
AX-2025-020132	ERP	ERP-2408-G8748	Kestrel	2025-Q1	99.66	4.65	100.3	Buyer-sourced	PASS

Other recent KP records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-043095	Retatrutide	KP-2607-H5774	Janoshik	2026-Q3	95.81	5.48	105.2	Buyer-sourced	0	FAIL
AX-2026-043094	Retatrutide	KP-2607-H5774	PeptideMeter	2026-Q3	96.32	6.40	—	Buyer-sourced	0	FAIL
AX-2026-043096	Retatrutide	KP-2607-H5774	VendorInvestigate	2026-Q3	96.48	6.05	104.9	Buyer-sourced	0	FAIL
AX-2026-043090	Retatrutide	KP-2607-H5774	Janoshik	2026-Q3	96.46	5.81	—	Buyer-sourced	0	FAIL
AX-2026-043091	Retatrutide	KP-2607-H5774	Janoshik	2026-Q3	96.13	5.94	—	Buyer-sourced	0	FAIL
AX-2026-043077	TB-500	KP-2605-C5214	Janoshik	2026-Q2	99.61	5.64	90.2	Buyer-sourced	0	PASS
AX-2026-043093	Retatrutide	KP-2607-H5774	Janoshik	2026-Q3	96.54	5.54	—	Buyer-sourced	0	PASS
AX-2026-043092	Retatrutide	KP-2607-H5774	Medutest	2026-Q3	96.64	6.12	—	Buyer-sourced	1	FAIL